Biofilm Disruptors in Wound Care Products: Moving Beyond Antimicrobials

Since the 1940s, antimicrobials have been our first line of defense in wound care. However, the very thing that has helped us fight infections is now starting to help the infections fight back. Structured communities of microorganisms, like bacteria, fungi, or yeast—called biofilms— are significantly more tolerant to antimicrobial treatments and harder to eradicate than free-floating cells. Even though there are effective biofilm disruptors making waves in the wound care field, more popular antimicrobial agents are still predominantly used worldwide. As a result, increased reliance on antimicrobials in biofilm-associated infections is helping drive the rise of antimicrobial resistance.

The solution is to rethink the design of wound care products. To effectively treat chronic wounds and combat antimicrobial resistance, manufacturers are exploring innovative approaches, such as integrating biofilm disruptors, that weaken bacterial defenses and improve treatment outcomes.

Why Are Traditional Antimicrobials Less Effective Against Wound Biofilms?

For decades, wound care has relied heavily on antimicrobial agents to control infection and promote healing. Among the most widely used are topical antibiotics, silver-based dressings, and antiseptic washes. These treatments are designed to reduce microbial load, prevent colonization, and create an environment conducive to tissue repair. 

However, these traditional strategies show significant limitations in chronic or complex wounds, particularly those complicated by biofilm formation. Antimicrobial agents often demonstrate short-term efficacy; they may kill free-floating bacteria initially but fail to prevent recolonization. 

Challenges associated with treating established wound biofilms include: 

• Limited antimicrobial penetration: The protective biofilm matrix can restrict the ability of antimicrobial agents to reach embedded microorganisms.
• Biofilm-associated tolerance: Microorganisms within biofilms may exhibit reduced susceptibility to antimicrobial treatments compared with free-floating cells.
• Persistent microbial populations: Surviving microorganisms may contribute to recolonization and recurring infections.
• Antimicrobial resistance: Biofilm environments can facilitate genetic exchange and contribute to the emergence or spread of resistance traits.

Once a biofilm has formed, even high concentrations of antimicrobials may be insufficient to eliminate the infection. 

A review from the National Library of Medicine highlights the need to rethink how we approach wound infections. To effectively treat chronic wounds and avoid exacerbating antimicrobial resistance, the next generation of wound care products must do more than kill bacteria. They must disrupt the protective environment that allows them to persist.

Biofilm Disruptors and Their Role in Wound Care

Biofilms are structured communities of microorganisms embedded within a self-produced matrix of extracellular polymeric substances, including proteins, polysaccharides, and DNA. This matrix acts as a scaffold that allows bacteria to adhere to wound surfaces and persist in the face of treatment. 

Biofilms are associated with the delayed healing and recurrence often observed in chronic wounds. One of their primary defense mechanisms is the physical barrier they create, which limits the ability of antimicrobial agents to reach the bacteria within. This shielding effect can reduce the impact of topical treatments. 

Importantly, biofilms are also associated with antimicrobial resistance. The enclosed biofilm environment promotes genetic exchange between bacteria and may increase the likelihood of resistance traits emerging or spreading. 

Biofilm disruptors target the protective structure that allows microbial communities to persist. By weakening or breaking down components of the extracellular matrix, these approaches may improve microbial accessibility to antimicrobial treatments. 

Breaking down the protective biofilm structure can enhance the performance of existing antimicrobials and open the door to non-antibiotic treatment approaches that may reduce reliance on traditional antibiotics. 

Engineering Wound Care Products With Biofilm Disruptors

Medical device manufacturers must consider biofilm-resistant strategies during development. This requires a strategic, interdisciplinary design mindset that integrates materials science, microbiology, and surface engineering from the outset. 

Choosing the right materials is critical. Several design considerations can influence microbial attachment and biofilm formation: 

• Material selection: Material properties can influence interactions between the wound dressing and microorganisms.
• Surface texture and porosity: These characteristics can affect bacterial adhesion and biofilm formation.
• Moisture interactions: How a material interacts with moisture can influence both fluid management and the ability of bacteria to adhere to the dressing.
• Biofilm-disrupting components: Incorporating disruptors into materials or surface coatings may help weaken the extracellular matrix and improve microbial accessibility to treatment.

Integrating biofilm disruptors into wound care materials can expose resident bacteria, making them more accessible to treatment. These approaches may improve antimicrobial efficacy while reducing reliance on traditional antibiotics. 

These combined strategies are important for enhancing antimicrobial efficacy and supporting wound healing. iFyber specializes in accelerating wound care innovation through custom, high-quality testing, with services tailored to answer important research questions at the earliest stages of development, before costly clinical studies or regulatory submissions.

Evaluating Biofilm-Disrupting Wound Care Products

Evaluating biofilm-disrupting wound care products requires understanding how materials and formulations influence microbial growth, biofilm formation, and antimicrobial performance under relevant experimental conditions.

iFyber supports wound care product innovation through complementary testing approaches:

• Customized Biofilm Assays: iFyber designs both in vitro and ex vivo models, including high-throughput 96-well biofilm susceptibility assays and ex vivo porcine and human dermal wound models, to simulate clinically relevant environments where biofilms are likely to form. These assays help researchers understand how materials or formulations perform before entering complex in vivo systems.
• Quantitative Antimicrobial Efficacy Testing: iFyber offers a range of validated methods, including minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays, time-kill studies, adhesion and attachment assays, and zone-of-inhibition assays. These methods help quantify how well a product inhibits or eliminates microbial growth, both with and without biofilms present.
• Simulated Wound Models: Developing wound care devices requires expertise in microbiology and mammalian cell culture. iFyber’s models go beyond basic planktonic bacterial testing, providing a more comprehensive evaluation of antimicrobial efficacy under wound-relevant conditions.
• Surface and Material Characterization: iFyber evaluates the physical and chemical properties of materials, such as hydrophobicity, surface topography, and porosity, that influence microbial adhesion and biofilm formation. This information can inform material selection and support product development.

How Can LC-MS Complement Biofilm Disruption Testing?

Conventional biofilm and antimicrobial assays help researchers evaluate changes in biofilm formation, microbial viability, and treatment effectiveness. However, these endpoints may not fully explain the biological processes associated with an observed treatment response.

LC-MS-based proteomics and metabolomics can provide complementary molecular evidence by characterizing changes in microbial protein abundance and metabolite profiles following exposure to biofilm-disrupting treatments. When integrated with microbiological testing, these approaches can help researchers:

• Investigate molecular responses: Identify protein and metabolite changes associated with biofilm disruption or antimicrobial treatment.
• Compare product formulations: Characterize molecular differences between treatments that produce similar effects on biofilm biomass or microbial viability.
• Inform further investigation: Identify molecular patterns and potential biological pathways that may help guide product optimization and additional research.

By connecting microbiological endpoints with molecular analysis, researchers can gain a more comprehensive understanding of treatment-associated responses and generate evidence to guide the development of biofilm-disrupting wound care products.

Supporting Innovation in Biofilm-Disrupting Wound Care Products

Leading developers of wound care products and medical devices know that demonstrating biofilm resistance and antimicrobial efficacy is a critical differentiator. iFyber partners with scientists, engineers, and R&D leaders to help bring these next-generation solutions to life.

Looking for a preclinical testing partner who understands your product challenges? iFyber combines microbiology, surface science, custom assay development, and complementary molecular analysis to support medical device teams from concept through commercialization. Reach out to discuss your research goals.